Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1379310 | 1.00 | CCR2 (1.00) | CCR2KCNH2 | |
| SCHEMBL1380859 | 0.94 | CCR2 (1.00) | CCR2KCNH2 | |
| SCHEMBL13612998 | 0.94 | CCR2 (1.00) | CCR2KCNH2 | |
| SCHEMBL1382791 | 0.93 | CCR2 (1.00) | CCR2KCNH2 | |
| SCHEMBL13612999 | 0.93 | CCR2 (1.00) | CCR2KCNH2 | |
| SCHEMBL1378111 | 0.93 | CCR2 (0.89) | CCR2KCNH2 | |
| SCHEMBL4562891 | 0.93 | CCR2 (0.89) | CCR2KCNH2 | |
| Pf-4136309 SCHEMBL13613003 | 0.91 | CCR2 (1.00) | CCR2KCNH2 | |
| Pf-4136309 SCHEMBL1377713 | 0.91 | CCR2 (1.00) | CCR2KCNH2 | |
| SCHEMBL1377360 | 0.91 | CCR2 (1.00) | CCR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170050942-A1 | 3-CYCLOALKYLAMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORP (US) | 2017-02-23 | — | — | US | disclosed |
| US-20090286792-A1 | 3-CYCLOALKYLAMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | XUE CHU-BIAO | 2009-11-19 | — | — | US | disclosed |
| US-7576089-B2 | 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors | INCYTE CORPORATION | 2009-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286792-A1 | 3-CYCLOALKYLAMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR2, CCR5, CXCR3 | CCR2 1/4885KCNH2 2769/4885 |
| US-20170050942-A1 | 3-CYCLOALKYLAMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR2, CCR5, CXCR3 | CCR2 1/4885KCNH2 2769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.